Key facts
- This page summarizes Stuart Woolf's Form 4 filing for MARRONE BIO INNOVATIONS INC.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2022, 16:08.
Stuart Woolf - 06 Apr 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 06 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2022, 16:08:26 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Linda V. Moore, as attorney in fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stuart Woolf filed Form 4 for MARRONE BIO INNOVATIONS INC on 08 Apr 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBII
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +11,000
- Change %
- Price
- $0.000000
- Shares after
- 11,000
- Date
- 06 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,000
- Exercise price
- Footnotes
- F1, F2
MBII
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 06 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
Footnote F2
Restricted stock units granted as compensation for serving on committees vest with respect to 100% of the total shares subject to the grant on April 6, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event.
Footnote F3
Restricted stock units granted as compensation for serving on the board vest with respect to 100% of the total shares on April 6, 2023, with pro rata vesting based on days elapsed since grant in event of a change in control event prior to that date. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event.